BRPI0821240B8 - formas mutantes de estreptolisina o - Google Patents

formas mutantes de estreptolisina o

Info

Publication number
BRPI0821240B8
BRPI0821240B8 BRPI0821240A BRPI0821240A BRPI0821240B8 BR PI0821240 B8 BRPI0821240 B8 BR PI0821240B8 BR PI0821240 A BRPI0821240 A BR PI0821240A BR PI0821240 A BRPI0821240 A BR PI0821240A BR PI0821240 B8 BRPI0821240 B8 BR PI0821240B8
Authority
BR
Brazil
Prior art keywords
streptolysin
mutant forms
forms
pyogenes
protection against
Prior art date
Application number
BRPI0821240A
Other languages
English (en)
Inventor
Bensi Giuliano
Margarit Y Ros Immaculada
Chiarot Emiliano
Grandi Guido
Scarselli Maria
Original Assignee
Novartis Ag
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Glaxosmithkline Biologicals Sa filed Critical Novartis Ag
Publication of BRPI0821240A2 publication Critical patent/BRPI0821240A2/pt
Publication of BRPI0821240B1 publication Critical patent/BRPI0821240B1/pt
Publication of BRPI0821240B8 publication Critical patent/BRPI0821240B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

FORMAS MUTANTES DE ESTREPTOLISINA O. Formas de GAS25 (estreptolisina O) que não são tóxicas, mas que ainda mantêm a habilidade para induzir proteção contra S. pyogenes são úteis em composições de vacina para indução de proteção contra S. pyogenes.
BRPI0821240A 2007-12-21 2008-12-18 formas mutantes de estreptolisina o BRPI0821240B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1619307P 2007-12-21 2007-12-21
US61/016,193 2007-12-21
US8838108P 2008-08-13 2008-08-13
US61/088,381 2008-08-13
PCT/IB2008/003725 WO2009081274A2 (en) 2007-12-21 2008-12-18 Mutant forms of streptolysin o

Publications (3)

Publication Number Publication Date
BRPI0821240A2 BRPI0821240A2 (pt) 2019-05-14
BRPI0821240B1 BRPI0821240B1 (pt) 2020-09-15
BRPI0821240B8 true BRPI0821240B8 (pt) 2022-10-04

Family

ID=40456773

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821240A BRPI0821240B8 (pt) 2007-12-21 2008-12-18 formas mutantes de estreptolisina o

Country Status (15)

Country Link
US (3) US7731978B2 (pt)
EP (2) EP2235046B1 (pt)
JP (2) JP5656642B2 (pt)
KR (2) KR101773114B1 (pt)
CN (2) CN104292312A (pt)
AU (1) AU2008339551B2 (pt)
BR (1) BRPI0821240B8 (pt)
CA (1) CA2709927C (pt)
DK (1) DK2235046T3 (pt)
ES (1) ES2391695T3 (pt)
NZ (2) NZ586430A (pt)
PL (1) PL2235046T3 (pt)
PT (1) PT2235046E (pt)
RU (1) RU2498994C2 (pt)
WO (1) WO2009081274A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE439372T1 (de) * 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
WO2006042027A2 (en) * 2004-10-08 2006-04-20 Novartis Vaccines And Diagnostics Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
AU2007348285A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
BRPI0821240B8 (pt) * 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o
MX2011002760A (es) * 2008-09-17 2011-06-16 Novartis Ag Vacunas y terapeuticos de combinacion contra el estreptococo del grupo a.
WO2012158216A1 (en) 2011-05-16 2012-11-22 Beech Tree Labs, Inc. Methods of treating a disorder associated with sequestered bacteria
WO2013157648A1 (ja) * 2012-04-19 2013-10-24 国立大学法人九州大学 医薬組成物
WO2017204325A1 (ja) * 2016-05-27 2017-11-30 東洋紡株式会社 改変型ストレプトリジンｏ
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN108611372B (zh) * 2018-05-14 2019-05-31 北京森康生物技术开发有限公司 一种免疫原性增强型猪传染性胃肠炎s基因复制缺陷型重组腺病毒的制备方法
CN115175697A (zh) * 2020-02-18 2022-10-11 Vaxcyte公司 具有多糖-蛋白质缀合物的a组链球菌免疫原性组合物
CN113880957A (zh) * 2021-11-04 2022-01-04 上海捷门生物技术有限公司 一种链球菌溶血素o融合蛋白
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
CN120005039B (zh) * 2025-01-10 2025-12-19 遵义医科大学珠海校区 HtsA-SLOdm融合蛋白及其在制备A族链球菌疫苗中的应用

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4454121A (en) * 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
CA1338800C (en) 1986-06-17 1996-12-17 Michael Houghton Hepatitis delta and diagnostics and vaccines
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5098827A (en) * 1988-02-26 1992-03-24 The University Of Florida Novel bacterial markers for pathogenic group B streptococci
US5523205A (en) * 1988-08-02 1996-06-04 Institut Pasteur DNA probes specific for hemolytic listeria
AU627226B2 (en) 1988-08-25 1992-08-20 Liposome Company, Inc., The Influenza vaccine and novel adjuvants
US5354846A (en) * 1988-11-18 1994-10-11 Michael Kehoe Streptolysin O antigen derivatives, its production and uses
GB8827038D0 (en) 1988-11-18 1988-12-21 Kehoe M Streptolysin o antigens & uses
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
MC2178A1 (fr) 1988-12-16 1992-05-22 Nederlanden Staat Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
GB2233977B (en) * 1989-01-04 1993-03-31 Michael Kehoe Cytolytic streptolysin o mutants and uses
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5821088A (en) * 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
US6737521B1 (en) * 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
ES2130177T3 (es) 1991-08-10 1999-07-01 Medical Res Council Tratamiento de poblaciones de celulas.
US5391712A (en) * 1991-08-30 1995-02-21 Beckman Instruments, Inc. Non-hemolytic streptolysin O variants
US5378620A (en) * 1991-08-30 1995-01-03 Beckman Instruments, Inc. Streptolysin O derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
EP0967279B1 (en) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DE4240056A1 (de) * 1992-11-28 1994-06-01 Boehringer Mannheim Gmbh Streptolysin O Peptidantigene und Verfahren zur Bestimmung von Streptolysin-Antikörper
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
DE69433581T2 (de) 1993-02-01 2005-03-03 Beckman Coulter, Inc., Fullerton Mitogener Faktor, sein Gen und Verfahren zur dessen Mikrodetektion
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
JP3644961B2 (ja) * 1993-06-23 2005-05-11 ベックマン コールター インコーポレイテッド ストレプトコッカス・ピオゲネスから誘導された組換えｄｎアーゼｂ
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
KR100341341B1 (ko) 1993-07-15 2002-11-25 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 이미다조[4,5-c]피리딘-4-아민
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE296877T1 (de) * 1994-10-07 2005-06-15 Univ Rockefeller Enzyme zur spaltung der verankerungsregion von oberflächenproteinen aus gram-positiven bakterien
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AUPM885194A0 (en) * 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6284884B1 (en) * 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US6936259B2 (en) * 1995-06-08 2005-08-30 University Of Saskatchewan CAMP factor of Streptococcus uberis
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
WO1997037026A1 (en) 1996-04-02 1997-10-09 Smithkline Beecham Corporation Novel compounds
US6346392B1 (en) 1996-11-27 2002-02-12 Smithkline Beecham Corporation Polynucleotides encoding a novel glutamine transport ATP-binding protein
WO1997043304A1 (en) 1996-05-14 1997-11-20 Smithkline Beecham Corporation Novel compounds
IES76925B2 (en) 1996-07-03 1997-11-19 Provost Subunit Vaccine for Streptococcus Equi
EP0821070A1 (en) 1996-07-22 1998-01-28 Carelli, Claude Marcel Henri Pit-1 gene polymorphism and trait selection in animals
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
DE69738525T2 (de) 1996-09-04 2009-02-19 Takara Bio Inc., Otsu Pilz-antigene und verfahren zu deren herstellung
CA2271720A1 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
JP2001510989A (ja) 1996-11-01 2001-08-07 スミスクライン・ビーチャム・コーポレイション 新規コーディング配列
US7033765B1 (en) * 1997-02-20 2006-04-25 Toronto Research Chemicals, Inc. Site-specific drug delivery
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
EP0981625A2 (en) * 1997-05-06 2000-03-01 Human Genome Sciences, Inc. $i(ENTEROCOCCUS FAECALIS) POLYNUCLEOTIDES AND POLYPEPTIDES
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
AU751009B2 (en) 1997-09-12 2002-08-08 University Of Tennessee Research Corporation, The Group A streptococcal vaccines
US6406883B1 (en) * 1997-09-26 2002-06-18 Luetticken Rudolf Lmb gene of Streptococcus agalactiae
EP1037997A1 (en) 1997-09-26 2000-09-27 Medimmune, Inc. Lmb gene of streptococcus agalactiae
US6756361B1 (en) 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
JP4402290B2 (ja) * 1997-10-17 2010-01-20 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 新規な乳酸菌種
EP1900818A3 (en) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
WO1999026969A1 (en) 1997-11-21 1999-06-03 University Of Otago Zoocin a immunity factor
JP2002536958A (ja) 1997-11-21 2002-11-05 ジェンセット Ｃｈｌａｍｙｄｉａｐｎｅｕｍｏｎｉａｅゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
EP2218732A1 (en) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
CN1285753A (zh) 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 透皮给药微粒疫苗组合物
JP2002508156A (ja) * 1997-12-31 2002-03-19 ストレスジェン バイオテクノロジーズ コーポレイション Ｈｓｐ６０ファミリーのＳｔｒｅｐｔｏｃｏｃｃｕｓ熱ショックタンパク質
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
US7041814B1 (en) * 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
TR200002437T2 (tr) 1998-02-20 2000-11-21 Biochem Pharma Inc. B grubu streptococcus antijenleri.
CA2290653A1 (en) * 1998-03-20 1999-09-30 Mount Sinai Hospital Streptococcus sag-a, a structural protein associated with sls activity
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9808327D0 (en) * 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds
EP2261347A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
GB9810193D0 (en) 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
US6660520B2 (en) * 1998-06-05 2003-12-09 Smithkline Beecham Corporation Nrde
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6936252B2 (en) * 1998-07-27 2005-08-30 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
US7098182B2 (en) * 1998-07-27 2006-08-29 Microbial Technics Limited Nucleic acids and proteins from group B streptococcus
MXPA01003557A (es) 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
US7128918B1 (en) * 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US7101692B2 (en) * 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
AU4989100A (en) 1999-05-04 2000-11-17 Susan A. Capizzi Method and apparatus for categorizing and retrieving network pages and sites
US6833356B1 (en) * 1999-08-25 2004-12-21 Medimmune, Inc. Pneumococcal protein homologs and fragments for vaccines
CO5200838A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
JP2003509473A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
WO2001022920A2 (en) * 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US6777547B1 (en) * 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
KR20020097200A (ko) * 2000-03-21 2002-12-31 엘리트라 파마슈티컬즈, 인코포레이티드 원핵세포에서의 필수유전자의 동정
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AUPQ801700A0 (en) * 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
WO2001098340A2 (en) 2000-06-23 2001-12-27 Bayer Aktiengesellschaft Regulation of human mast cell protease 6-like enzyme
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
WO2002004495A2 (en) * 2000-07-06 2002-01-17 Shire Biochem Inc. Streptococcus pyogenes antigen
AU2001281168A1 (en) * 2000-08-08 2002-02-18 St. Jude Children's Research Hospital Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
AU8743001A (en) 2000-08-28 2002-03-13 Aventis Pasteur Moraxella polypeptides and corresponding dna fragments and uses thereof
ATE384072T1 (de) 2000-09-26 2008-02-15 Idera Pharmaceuticals Inc Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
WO2002057315A2 (en) * 2000-10-10 2002-07-25 University Of Tennessee Research Corporation Streptococcal streptolysin s vaccines
US7160547B2 (en) * 2000-10-10 2007-01-09 University Of Tennessee Research Corporation Streptococcal streptolysin S vaccines
ATE439372T1 (de) * 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
PT1372708E (pt) 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
CA2441530A1 (en) 2001-03-19 2002-09-26 Iomai Corporation Transcutaneous immunostimulation
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
US20070128229A1 (en) * 2002-04-12 2007-06-07 Wyeth Surface proteins of Streptococcus pyogenes
JP2004533236A (ja) * 2001-04-13 2004-11-04 ワイエス 化膿性連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｙｏｇｅｎｅｓ）の表面タンパク質
CA2881980A1 (en) 2001-05-18 2002-11-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
CA2492823A1 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
EP2168596B1 (en) 2001-12-12 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
GB2385274B (en) * 2002-02-13 2004-04-14 Ming-Jeng Shue Vaginal suppository delivery device
US20050181388A1 (en) * 2002-04-02 2005-08-18 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from bacteria
WO2003087353A2 (en) * 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in membrane biogenesis
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
WO2004041157A2 (en) 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine
TW566366U (en) * 2002-09-27 2003-12-11 Wus Tech Co Ltd Labor-saving portable battery equipment for power-driven walking assisted scooter
EP2314603A3 (en) * 2002-10-15 2011-05-18 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof
US7521062B2 (en) 2002-12-27 2009-04-21 Novartis Vaccines & Diagnostics, Inc. Thiosemicarbazones as anti-virals and immunopotentiators
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
EP1601770B1 (en) * 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigens
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
EP1620460A2 (en) * 2003-05-07 2006-02-01 Intercell AG Streptococcus agalactiae antigens i + ii
CA2526106A1 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
JP4875490B2 (ja) * 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物
AU2003904237A0 (en) * 2003-08-08 2003-08-21 Garvan Institute Of Medical Research Novel translocation assay
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
RU2263143C2 (ru) * 2004-01-05 2005-10-27 ГНУ Научно-исследовательский институт пушного звероводства и кролиководства им. В.А. Афанасьева Штамм бактерий streptococcus pyogenes №289, используемый для изготовления вакцин против стрептококкоза пушных зверей
KR101178776B1 (ko) * 2004-02-06 2012-09-07 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 치료학적 잠재성을 가진 어드헤신 및 어드헤신계 단백질을 동정하기 위한 컴퓨터 장치
US20060041961A1 (en) * 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
WO2005108419A1 (en) * 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
US20060165716A1 (en) * 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
AU2005335216A1 (en) * 2004-10-05 2007-02-15 Wyeth Probe arrays for detecting multiple strains of different species
EP1770171A1 (en) 2005-09-29 2007-04-04 Universität Zu Köln DNA microarray for rapid identification of Candida albicans in blood cultures.
US9370557B2 (en) * 2006-06-15 2016-06-21 The University Court Of The University Of Glasgow Adjuvant compounds
EP2319862A1 (en) 2006-07-07 2011-05-11 Intercell AG Small Streptococcus pyogenes antigens and their use
AU2007348285A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
BRPI0821240B8 (pt) * 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o

Also Published As

Publication number Publication date
US20090162392A1 (en) 2009-06-25
KR20100113089A (ko) 2010-10-20
PT2235046E (pt) 2012-10-26
RU2498994C2 (ru) 2013-11-20
AU2008339551A1 (en) 2009-07-02
EP2235046A2 (en) 2010-10-06
EP2537857B1 (en) 2017-01-18
US20100158935A1 (en) 2010-06-24
NZ586430A (en) 2012-09-28
CA2709927A1 (en) 2009-07-02
DK2235046T3 (da) 2012-10-29
US20120003258A1 (en) 2012-01-05
ES2391695T3 (es) 2012-11-29
BRPI0821240A2 (pt) 2019-05-14
EP2235046B1 (en) 2012-08-01
WO2009081274A3 (en) 2009-08-13
AU2008339551B2 (en) 2013-10-24
NZ601543A (en) 2013-03-28
CN101977926A (zh) 2011-02-16
KR101773114B1 (ko) 2017-08-30
KR20160114196A (ko) 2016-10-04
RU2010130338A (ru) 2012-01-27
BRPI0821240B1 (pt) 2020-09-15
EP2537857A2 (en) 2012-12-26
PL2235046T3 (pl) 2012-12-31
CN101977926B (zh) 2014-10-08
US8409589B2 (en) 2013-04-02
EP2537857A3 (en) 2013-01-02
JP2011507500A (ja) 2011-03-10
US7731978B2 (en) 2010-06-08
JP2014027946A (ja) 2014-02-13
US8039005B2 (en) 2011-10-18
CN104292312A (zh) 2015-01-21
JP5656642B2 (ja) 2015-01-21
WO2009081274A2 (en) 2009-07-02
CA2709927C (en) 2017-05-16

Similar Documents

Publication Publication Date Title
BRPI0821240A2 (pt) formas mutantes de estreptolisina o
BRPI0815008B8 (pt) vacinas multiméricas com múltiplos epítopos contra influenza
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
CO6331298A2 (es) Vacunas contra coccidiosis
MX375444B (es) Composiciones sinergicas que comprenden una cepa de bacillus subtilis y un bioplaguicida.
CL2013000396A1 (es) Composicion que comprende bacillus subtilis y bacillus licheniformis; proceso para elaborar dicha composicion; uso de dicha composición para el control de los fitonematodos y/o en la introduccion de una resistencia especifica a ellos.
HN2008001464A (es) Formulaciones para administrcion parenteral de compuestos y sus usos
MX2010008799A (es) Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
CL2011002849A1 (es) Composicion anti-inflamatoria que comprende microorganismos sometidos a tratamiento a por lo menos 71,5 grados celsius durante por lo menos 1 segundo; uso de una composicion para tratar o prevenir padecimientos inflamatorios; metodos para proporcionar los microorganismos.
MX383908B (es) Formulaciones desinfectantes tópicas y uso de las mismas.
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
CR20110553A (es) Terapia complementaria contra el cáncer
CL2007003060A1 (es) Compuestos derivados de piridazina; proceso para la preparacion de dichos compuestos; composicion fungicida para controlar o proteger contra microorganismos fitopatogenicos;uso de dichos compuestos; y metodo para controlar o proteger contra microorganismos fitopatogenicos.
CL2008003712A1 (es) Compuestos derivados de tiadiazololoxifenilamidina o tiazoliloxifenilamidina; su procedimiento de preparacion; uso y procedimiento para combatir microorganismos no deseados; agente que comprende a dichos compuestos; compuestos intermediarios; y su procedimiento de preparacion.
MX2010005589A (es) Composicion para el cuidado personal.
AR058501A1 (es) Composiciones azeotropicas que comprenden 1,1,1,2,3- pentalfluoropeno y fluoruro de hidrogeno y sus usos
CO7250444A2 (es) Uso de seaprose para eliminar biopelículas bacterianas
MX2011007456A (es) Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
NI201400065A (es) Preparaciones que comprenden emodépsido amorfo
FR2977256B1 (fr) Compositions de 2,4,4,4-tetrafluorobut-1-ene et de cis-1,1,1,4,4,4-hexafluorobut-2-ene
BR112013028607A2 (pt) composições sólidas contendo éter glicólico e água
MX375183B (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
MX381118B (es) Composicion de eliminacion de contaminacion y su uso.
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. (BE)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2859 DE 21-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.